Demographic and baseline characteristics of the study population at V1
| INCO (n=108) | CON (n=110) | |
|---|---|---|
| Male gender (n) | 58 (53.7%) | 70 (63.6%) |
| Female gender (n) | 50 (46.3%) | 40 (36.4%) |
| Age (years) | 61.7±12.9 | 67.8±12.7 |
| Body mass index (kg/m2) | 26.7±4.1 | 27.7±4.8 |
| Time since stroke (years) | 7.5±5.8 | 5.3±5.1 |
| Type of stroke | ||
| Ischaemic | 51 (47.2%) | 43 (39.1%) |
| Haemorrhagic | 16 (14.8%) | 7 (6.4%) |
| Others | 21 (19.4%) | 29 (26.4%) |
| No data | 20 (18.5%) | 31 (28.2%) |
| Duration of upper limb spasticity (years) | 6.6±6.3 | 4.9±5.4 |
| Previous antispastic medication (n) | 85 (78.7%) | 65 (59.1%) |
| Previous botulinum toxin therapy (n) | 67 (62%) | 0 |
Data are mean±SD or number of patients (%).
CON, patients receiving conventional therapy; INCO, patients receiving incobotulinumtoxinA.